Analysis Of Income And Expense [Abstract]

Xspray Pharma - Filing #690674

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	– SEK	—	—	—	—	—	– SEK	—
Material income and expense [abstract]
Research and development expense	—	—	22 219 SEK	—	—	—	—	—	38 567 SEK	—
Finance income (cost)	—	—	1 403 SEK	—	—	—	—	—	1 255 SEK	—
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	—	—	109 601 SEK	—	—	—	—	—	58 384 SEK	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– SEK	– SEK	131 670 SEK	131 670 SEK	– SEK	– SEK	– SEK	– SEK	96 698 SEK	96 698 SEK